Search results
Showing 16 to 30 of 692 results for innovative
agents. Medical technologies guidance This guidance evaluates new, innovative medical devices and diagnostics. It looks at medical...
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.
This guideline covers how local communities, with support from local organisations and networks, can help prevent people from becoming overweight or obese or help them lose weight. It aims to support sustainable and community-wide action to achieve this.
In development [GID-HTE10050] Expected publication date: 28 May 2025
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment
In development [GID-HTE10056] Expected publication date: 24 April 2025
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
In development [GID-TA11461] Expected publication date: 16 April 2025
Cladribine for treating relapsing multiple sclerosis [ID6263]
In development [GID-TA11293] Expected publication date: 23 April 2025